Skip to content
Health

Breckenridge Pharmaceutical Recalls Propranolol Capsules Over Metal Contamination

The voluntary nationwide recall affects a specific lot of 60 mg extended-release capsules distributed to pharmacies and wholesalers.

By 2 min read

Breckenridge Pharmaceutical Inc. has initiated a voluntary nationwide recall of one lot of its 60 mg propranolol hydrochloride extended-release capsules. The recall, conducted with the knowledge of the U.S. Food and Drug Administration, was prompted by concerns that the medication may contain metal contamination.

The affected product is packaged in 100-count bottles identified by lot number PK25110035, which carries an expiration date of May 2029 and a National Drug Code of 51991-817-01. According to the company, these capsules were manufactured by Adare Pharma Solutions and were distributed to wholesalers and pharmacies across the United States between October 26 and November 4, 2026.

The company stated that the decision to recall the lot followed the discovery that it shared intermediate materials with a separate batch that had been identified as containing metal. While that initial batch was never released to the market, the company opted to pull the distributed lot as a precautionary measure.

Breckenridge Pharmaceutical warned that the presence of metal particles in the capsules could pose significant health risks to patients. The company noted that ingestion of the product could potentially cause "lacerations of soft tissues in the oral cavity, esophagus, stomach, or intestine." Despite these risks, the manufacturer reported that it is not currently aware of any adverse events or injuries related to the use of the recalled medication.

Patients currently in possession of the affected capsules are advised to stop taking the medication immediately. The company recommends that individuals contact their healthcare providers to discuss medical advice and obtain instructions for a replacement. Any unused portions of the medication should be returned to the pharmacy where the prescription was originally filled.

Wholesalers, pharmacies, and other retailers have been instructed to inspect their current inventories, quarantine the affected lot, and cease all distribution. For those seeking further information or assistance, the company has engaged Qualanex as a recall service provider. Inquiries can be directed to 1-855-736-0807 or via email at recall@qualanex.com during standard business hours.

Propranolol hydrochloride extended-release capsules are commonly prescribed as a beta-blocker to help manage conditions such as high blood pressure and heart disease. By lowering heart rate and blood pressure, the medication assists the body in circulating blood more efficiently. Health officials encourage patients to report any adverse reactions or quality concerns to the FDA’s MedWatch program.

Sources

Related stories